Drug Trial Radar · NCT06445062
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,130
Planned (sponsor's estimate)
Start
May 24, 2024
Primary completion
Sep 30, 2028
Study completion Mar 30, 2030
Sponsor
- Lead sponsor
- Revolution Medicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol G: RMC-9805 + cetuximab + FOLFIRI
Conditions
- Colorectal Cancer
- CRC
- Pancreatic Ductal Adenocarcinoma
- PDAC
- Gastrointestinal Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
RMC-6236Drug
Oral tablet
mFOLFOX6 regimenDrug
IV infusion
bevacizumabDrug
IV infusion
mFOLFIRINOX regimenDrug
IV infusion
cetuximabDrug
IV infusion
gemcitabineDrug
IV infusion
nab-paclitaxelDrug
IV infusion
RMC-9805Drug
Oral Tablet
FOLFIRI regimenDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (Subprotocols A-F)Time frame: Up to 3 years
- Dose limiting toxicities (Subprotocols A-F)Time frame: 28 days
- Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)Time frame: Up to 3 years
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers
Chandler, Arizona · Recruiting
Mayo Clinic Hospital
Phoenix, Arizona · Recruiting
HonorHealth Research Institute
Scottsdale, Arizona · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
Cedars-Sinai Cancer at Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
UCLA Hematology/Oncology- Santa Monica
Los Angeles, California · Recruiting
University of Colorado Hospital-Anschutz Cancer Pavilion
Aurora, Colorado · Recruiting
Yale-New Haven Hospital-Yale Cancer Center
New Haven, Connecticut · Recruiting
Mayo Clinic Cancer Center
Jacksonville, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
The University of Kansas Clinical Research Center
Westwood, Kansas · Recruiting
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Atlantic Health System
Morristown, New Jersey · Recruiting
Northwell Health / RJ Zuckerberg Cancer Center
Lake Success, New York · Recruiting
Columbia University Medical Center
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center Main Campus
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Recruiting
Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology Dallas
Irving, Texas · Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.